Dr. Lal Pathlabs Limited - Earnings Release 2025

==> picture [598 x 66] intentionally omitted <==

October 23, 2024

National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524

Sub: Press Release on Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2024

Dear Sir/ Madam,

Please find enclosed herewith the Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2024.

We request you to please take the same on record.

Thanking You, Yours Faithfully,

For Dr. Lal PathLabs Limited

VINAY Digitally signed by VINAY GUJRAL GUJRAL Date: 2024.10.23 15:54:18 +05'30'

Vinay Gujral Company Secretary & Compliance Officer

Encl.: As above

Classification: Internal

For Immediate Release

==> picture [159 x 37] intentionally omitted <==

October 23, 2024

Dr Lal PathLabs Limited records revenue of Rs 660 Cr in Q2 FY 2024-25

New Delhi, India, October 23, 2024 – Dr Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended September 30, 2024.

Consolidated Performance Highlights: Q2 FY25 vs Q2 FY24

Revenue increased by 9.8% in Q2 FY25
EBITDA increased by 13.9% with a margin of 30.7%
PAT increased by 18.1% with a margin for of 19.8%
Second Interim Dividend of Rs. 6 per share for FY25

Financial Overview (Consolidated) in Rs Cr

==> picture [454 x 265] intentionally omitted <==

Dr Lal Pathlabs Limited

12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com

==> picture [159 x 37] intentionally omitted <==

About Dr Lal PathLabs Limited

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its’ integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2024 the company has 280 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 5,762 Patient Service Centers (PSCs) and 11,619 Pick-up Points (PUPs). Its’ customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Goel Group Chief Financial Officer Dr Lal PathLabs Limited

+91 124 3016500 [email protected]

Kritika Khatwani Adfactors PR

+91 8604801332 [email protected]

For further information on Dr Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.